Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies
Mengshi Tang, Yingxu Ma, Yating Wang · 2026
Read Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies by Mengshi Tang, Yingxu Ma, Yating Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13275242.txt.
Description
Mengshi Tang, Yingxu Ma, and Yating Wang ranked drug treatments for fatty liver disease with scarring risk in a 2026 network meta-analysis. This condition, called MASH, can be attacked through several hormone and metabolic pathways, and many drug classes show promise. Recent trials of an oral diabetes class had not yet been placed in the ranking.
They gathered thirty-four phase two and three trials in adults with biopsy proven disease. For shrinking liver scarring, FGF21 analogs and the SGLT2 inhibitor class ranked at the top, ahead of the one approved drug and GLP-1 drugs. For clearing the disease itself, dual hormone agonists and FGF21 analogs led. A balance chart put SGLT2 inhibitors in the best zone of effect and tolerability, though their tissue data rest on a single pivotal trial.
Catalog record
| CREATOR | Mengshi Tang, Yingxu Ma, Yating Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |